Bacteriophage Therapy Market – Trend, Growth, Forecast 2024–2032

The Bacteriophage Therapy Market Was Valued at USD 1.32 Billion in 2023 and is Projected to Reach USD 1.87 Billion by 2032, Growing at a CAGR of 3.89 % from 2024 to 2032.

The Bacteriophage Therapy Market is growing in popularity as a promising option to traditional antibiotics, fueled by increasing worries about antibiotic resistance and the drawbacks of standard treatments for bacterial infections. Bacteriophages, which are viruses that target and kill bacterial cells with precision, provide a specific method to fight bacterial infections without causing harm to beneficial microbiota. This special method is very attractive for treating infections that are resistant to multiple drugs, especially in patients who cannot handle antibiotics or have tried all other options. Consequently, research institutions, biotechnology companies, and healthcare providers are more and more investigating bacteriophage therapy as a possible answer to the worldwide issue of antibiotic resistance.

Major investments in research and development are driving the market's expansion, supporting the creation of bacteriophage treatments for a range of uses like treating wounds, respiratory illnesses, and gastrointestinal issues. Furthermore, the increasing prevalence of healthcare-associated infections (HAIs) and infectious diseases on a global scale, along with regulatory backing for alternative therapies, is fuelling the need for bacteriophage-based solutions. Although there are obstacles related to regulations and worries about the standardization of bacteriophage preparations, progress in genetic engineering and synthetic biology is leading to improved bacteriophage efficacy and broader clinical usefulness.